327 results about "Ischemic stroke" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of a targeted liposome as an active component in preparation of a medicine for treating ischemic brain injury. The targeted lipidosome for treating cerebral arterial thrombosis is prepared by fusing the lipidosome and the platelet-neutrophil aggregate membrane, realizes efficient and specific targeting of an ischemic brain region, effectively reduces brain tissue infarction and damage of a new region, relieves brain inflammation through multi-channel regulation and control, and improves the cerebral arterial thrombosis treatment effect. The compound can be used as an active ingredient for preparing a medicine for treating ischemic brain injury. And after the target liposome is further coated with a rutin drug, the synergistic treatment effect is realized. The liposome medicine can be used as an active component and has a good application prospect in treatment of ischemic brain injury diseases.

APRIL research shows that in a selected stroke patient, infusion of 0.2 mg / kg of ApTOLL (SEQ ID NO: 1) in combination with intravascular treatment is safe, and the death rate of 90 days is reduced. ApTOLL has proved to limit intracranial hemorrhage and reperfusion injury which may occur after recanalization, and also improve early nerve injury and long-term disability. ApTOLL molecules are provided for reducing the risk of intracranial or secondary bleeding after acute ischemic stroke, reducing nerve injury, and improving nerve recovery in a subject.

The invention provides a multi-modal cerebral arterial thrombosis medical image segmentation method, device and equipment, and the method comprises the steps: extracting the independent features of different modal medical images through combining a ViT encoder branch and a CNN encoder branch which are finely adjusted by a hybrid expert as a multi-modal image double-branch coding network; further integrating complementary information of different modes by using a mode missing adaptive fusion network, and performing global-local information interaction between CNN features and ViT features by using an encoder branch interaction network, so that specific features and cross-mode invariant features of different available modes can be decoupled under the condition of mode missing; and meanwhile, the advantages of different types of features are fully utilized, and the value information of the multi-modal image features is deeply mined, so that accurate multi-modal cerebral arterial thrombosis medical image segmentation and imaging are realized, and the method is high in reliability, good in accuracy and good in practicability.

Provided are an siRNA which inhibits plasma coagulation factor XI gene expression, a pharmaceutical composition containing the siRNA, a conjugate, a reagent kit, and a use of the siRNA, the pharmaceutical composition thereof and the conjugate in preparing a drug used for treating and / or preventing thrombotic diseases and ischemic strokes.

The invention discloses a potential stroke risk assessment method and system after coronary artery recanalization, and the method comprises the steps: obtaining the heart and cerebral vessel image data of a patient, and constructing a complete heart and cerebral artery blood vessel geometric model; based on the cardio-cerebral artery blood vessel geometric model, numerical simulation is conducted on the flowing conditions of blood flow in coronary arteries and cerebral vessels by means of a computational fluid mechanics method, and the pressure ratio before and after coronary artery stenosis and the partial pressure ratio of the cerebral vessels are calculated; according to the pressure ratio and the partial pressure ratio, the potential risk of the cerebral arterial thrombosis is quantitatively evaluated, and a cerebral blood flow partial pressure ratio numerical value and a cerebral arterial thrombosis risk evaluation report are generated. According to the cerebral apoplexy risk quantitative evaluation method, by integrating coronary artery CTA and cranial CTA or MRA data, reconstructing a complete heart and cerebral vessel geometric model and simulating heart and cerebral blood flow changes before and after a coronary artery recanalization operation, and particularly by calculating coronary artery FFR and cerebral blood flow partial pressure ratio FPR, an evaluation report is generated, and a basis for quantitative evaluation of the cerebral apoplexy risk in the operation is provided for clinical doctors.

Described herein are compounds and methods of treating or imaging a disease or disorder, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of a cromolyn ester.

The invention discloses a nasal delivery multistage targeting bionic nano drug delivery system as well as a preparation method and application of the nasal delivery multistage targeting bionic nano drug delivery system. According to the drug delivery system, a black phosphorus nanosheet with an active oxygen scavenging effect is used as an inner core carrier, a neuroprotective agent fingolimod hydrochloride FTY720 and polydimethyldiguanide PolyMet are loaded, and a microcolloid cell membrane and a mitochondrial membrane are modified on the surface of the preparation; the nano drug delivery system is applied to treatment of cerebral arterial thrombosis reperfusion injury, can overcome the blood brain barrier, can quickly enter the brain through nasal administration, realizes efficient delivery of drugs, remarkably reduces the cerebral infarction area, reduces the brain inflammation level, protects nerve cells, greatly relieves cerebral arterial thrombosis reperfusion injury, and has application prospects.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to N-methylation modified cyclopeptide and application thereof. On the basis of a GluA2-3Y polypeptide sequence, chemical modification and transformation of amido bond N-methylation and head-tail cyclization are carried out, the N-methylation modified cyclopeptide with stable metabolism and good permeability is obtained, and the endocytosis of a GluA2AMPA receptor is blocked to protect nerve cells, so that the GluA2AMPA receptor can be effectively inhibited, and the GluA2AMPA receptor can be effectively inhibited. The invention also provides application of the cyclic peptide in preparation of drugs for treating cerebral arterial thrombosis.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

The invention discloses application of (20S)-ginsenoside Rh1 in preparation of drugs for preventing and / or improving cerebral arterial thrombosis, and relates to the technical field of medical application of natural drugs. The invention verifies that (20S)-ginsenoside Rh1 up-regulates the expression of an anti-apoptosis gene by promoting STAT3 phosphorylation and translocation to a cell nucleus, so that the (20S)-ginsenoside Rh1 plays a role in protecting neuronal injury induced by sugar oxygen deprivation. In MCAO model mice, the (20S)-ginsenoside Rh1 obviously relieves the symptom of ischemic cerebral apoplexy and has positive influence on neurodegenerative events related to cerebral infarction, and the anti-apoptosis and neuroprotection effects are most prominent. Mechanism research shows that (20S)-ginsenoside Rh1 plays a therapeutic role in PC12 cell and MCAO model mice by activating a JAK2 / STAT3 signal channel.

The invention belongs to the field of medical image processing, and provides a thrombus composition visual navigation method based on a CT image, which comprises the following steps: step 1, evaluating the CT image, and sketching thrombus according to the CT image of a stroke patient; 2, feature selection and model construction, wherein thrombus is divided into different areas; 3, performing histological evaluation, and associating different regions with tissue components; 4, outputting to a user: extracting the characteristics of each region to predict the prognosis of the patient; and fusing the CTA image and the DSA image, performing thrombus extraction navigation, and automatically and visually presenting different regions of thrombus components. The invention provides a visualization method for helping doctors to evaluate thrombus components of ischemic stroke patients.

The invention provides an extract extracted from rhodiola rosea and used for preventing and treating cerebral arterial thrombosis, which is prepared by the following steps: obtaining a dry rhodiola rosea raw material, and crushing the raw material; performing extraction treatment on the crushed raw materials by adopting an ethanol solution to obtain an extracting solution; carrying out concentration treatment on the extracting solution to obtain an extract; dissolving the extract in water, and carrying out separation treatment to obtain supernate; adjusting the pH value of the supernate; carrying out adsorption and purification treatment on the supernatant with the adjusted pH value to obtain an eluent; and concentrating and drying the eluent to obtain the extract.

Disclosed in the present invention is the use of a mesenchymal-stem-cell-derived intracellular nanovesicle in neuroprotection. Compared to a small extracellular vesicle with exosomes as the main component, the small intracellular nanovesicle of the present invention has a smaller particle size, a narrower particle size distribution range, and greater stability at different temperatures, and has good tissue compatibility. The small intracellular nanovesicle of the present invention can better ameliorate nerve injury or neurodegenerative diseases such as optic nerve injury, ischemic stroke and Alzheimer's disease, and has very good application and research value in the field of pharmaceuticals.

A balloon expandable stent having multiple rings and cells with ultra-thin struts, wherein the sizes of the cells are larger proximally and varies amongst the rings, enabling the stent to expand to a larger diameter at its proximal end compared with the distal end. A conical shape rather than the classic cylindrical design post deployment ensures adequate opposition of the stent to the arterial wall and avoids supramaximal expansion at the distal end. A unique monorail angioplasty balloon catheter delivers the stent through tortuous intracranial arteries with longer working length. A longer segment with traversing microwire enables modification in stiffness depending on stiffness of microwire, and reduction in length of segment with a hypotube alone.

The invention provides an ischemic stroke auxiliary diagnosis system based on a peripheral blood T cell single cell transcriptome and application thereof, and the auxiliary diagnosis system comprises a peripheral blood mononuclear cell acquisition module, a single cell RNA sequencing module, a data processing module, a data analysis module and a result discrimination module. With a coding gene of a protein molecule significantly related to the occurrence of ischemic stroke as a target gene, a data processing module obtains the expression level of the target gene in each T cell; the data analysis module obtains a risk score of each T cell of the subject by using a built-in single cell risk scoring model, and weights the risk scores of all the T cells through distributed perception identification to obtain an individual risk score of the subject; and the result judgment module is used for classifying the subjects into ischemic stroke negative and ischemic stroke positive according to the individualized risk scores of the subjects. The auxiliary diagnosis system disclosed by the invention is high in ischemic stroke discrimination capability, and high in sensitivity and specificity.

The invention discloses application of eugenin in preparation of a medicine for treating cerebral arterial thrombosis, and belongs to the technical field of medicines. An in-vivo middle cerebral artery occlusion model is adopted, after reperfusion is conducted for 24 h, the cerebral infarction volume and movement coordination function defect of a mouse are detected to evaluate the treatment effect of eugenin, and activation of microglial cells and survival of neuronal cells are observed through immunofluorescence to clarify the action way of eugenin. Pharmacological activity shows that eugenin can obviously reduce the cerebral infarction volume of a model mouse, improve pathological damage of cells and promote recovery of a motion coordination function, and the action way of eugenin is to promote survival of neuronal cells and inhibit activation of microglial cells. Research results indicate that eugenin has the effect of resisting cerebral arterial thrombosis and can be used as a candidate medicine for developing the cerebral arterial thrombosis resisting medicine.

A glycoside drug oral preparation for treating cerebral ischemic stroke during the recovery period and a preparation method therefor. The glycoside drug is (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(4-(4-methoxyphenyl)butoxy)tetrahydro-2H-pyran-3,4,5-triol. The oral preparation can provide a high drug loading capacity, release the drug within a short time period, and ensure rapid drug dissolution, and the prepared tablet has high stability, involves a simple preparation process and is suitable for large-scale industrial production.

The scheme provides a kind of engineered exosome double drug delivery system loaded with ergosterol and its preparation method and application, belongs to the field of nanomaterials and nanobiomedicine, based on the innovative ROS-responsive nanomaterial CHPG design, load the active ingredient ergosterol to play the role of treatment and repair, which realizes the blood-brain barrier penetration and precise drug release in lesion area through targeted functional modification;It is wrapped in the nasal mucosa-derived stem cell exosome to form a drug delivery system Exo@Erg-CHPG-M, which combines the natural biological characteristics of exosome and the precise targeting advantage of nanomicelle, significantly improves the drug delivery efficiency, in vitro and animal model verification show that, the system can improve the neurological impairment and brain tissue injury after ischemic stroke by synergistically regulating inflammation and neural repair pathways, the scheme provides a new technical scheme for the precise treatment of central nervous system diseases such as cerebral stroke.

The present invention relates to a biomarker composition for diagnosing stroke or post-stroke neurological damage, for diagnosing the severity of stroke or post-stroke neurological damage, and for predicting stroke prognosis, and the like. Using an ischemic stroke mouse disease model, a tissue damage analysis and a behavioral analysis were performed, and the mRNA level expression was confirmed, and as a result, Prox1 or Dcx could be selected as a biomarker. In addition, it was confirmed that the expression of Prox1 or Dcx increased as the severity of stroke or post-stroke neurological damage was higher, and thus the present invention is expected to be useful for diagnosing stroke or post-stroke neurological damage, for diagnosing the severity of stroke or post-stroke neurological damage, and for predicting stroke prognosis.

The invention belongs to the field of in-vitro diagnostic reagents, and particularly relates to application of a reagent for detecting biomarkers in serum in preparation of a cerebral arterial thrombosis diagnostic kit. The invention determines that the concentrations of lactic acid, isoleucine, fumaric acid, ketoglutaric acid, hypoxanthine, tyrosine, histidine and inosine in serum of a cerebral arterial thrombosis (IS) patient are significantly related to major atherosclerosis (LAA) and minor artery occlusion (SAO), so that the concentrations of the biomarkers can be used as a basis for diagnosing IS and distinguishing LAA and SAO.

The present application relates to the technical field of medicine, and provides a kind of haena polysaccharide and its preparation method and application and target endogenous coagulation pathway anticoagulant and / or antithrombotic drug.The haena polysaccharide provided by the present application is fucosylated chondroitin sulfate polysaccharide, the weight average molecular weight is 9-13 million, the molar ratio of glucuronic acid, N-acetylglucosamine and fucose is 1:0.8-1.2:0.5-0.8, and the mass percentage content of sulfate group is 25-40%.The haena polysaccharide provided by the present application can target endogenous coagulation pathway terminal rate-limiting enzyme (iFXase), and has no obvious effect on coagulation factors in other coagulation pathways, realizes the effect of anticoagulation and non-hemorrhage, and can be widely applied in acute and recovery period treatment of ischemic stroke, solves the safety problem of using anticoagulant and antithrombotic drug for clinical ischemic stroke patients, and opens up a new field of research and development of target endogenous coagulation pathway rate-limiting enzyme anticoagulant drug.

The invention relates to a structural network-genetic map biological network model for predicting ischemic stroke and a construction method thereof, and the method comprises the steps: extracting and calculating seven multi-scale morphological features and pairwise Pearson correlation coefficients among the features from T1 weighted imaging data and diffusion tensor imaging data; constructing a 308 * 308 morphological similarity network matrix and a brain network module for identifying ischemic stroke neural dysfunction; 1782 sampling points are extracted from the Airy human brain map, and each sampling point comprises expression data of 10185 genes; the method comprises the following steps: mapping space coordinates of AHBA sampling points to a cortex package of a Desikan-Killiany map, carrying out normalization processing to output 308 * 10185 brain region gene-by-gene expression matrixes, and constructing a structural network-gene map biological network model for predicting ischemic stroke by adopting a partial least square regression method and a bootstrap method. Compared with the prior art, the model determines the specific molecular mechanism related to the phenotypic structure change of ischemic stroke injury, and the stroke occurrence probability is predicted according to the specific molecular mechanism.

The present application relates to a kind of hyperbranched polymer, nano preparation and its preparation method and application, belong to functional medical material and nanotechnology field.The hyperbranched polymer of the present application can be broken in ROS environment Release dihydrolipoic acid, play the role of antioxidant, be reduced to lipoic acid in vivo, and then play its role as coenzyme, participate in mitochondrial tricarboxylic acid cycle, restore mitochondrial function, thereby play the role of antioxidant and play the role of treating ischemic stroke.The nano preparation provided by the present application can be quickly distributed to brain in a short time, temporarily increase the paracellular permeability of BBB by inhibiting the expression of multi-drug resistance protein P-gp and ATP-dependent drug efflux protein on BBB, and the process of opening BBB by borneol is physiological and reversible, without destroying the structural integrity of blood-brain barrier.

The invention provides an ergosterol-loaded engineered exosome double-drug-loading system as well as a preparation method and application thereof, belongs to the field of nano materials and nano biological medicines, and is based on innovative ROS response type nano material CHPG design, a therapeutic active component ergosterol is loaded to play a role in treatment and repair, and the curative effect of the ergosterol is improved. Blood-brain barrier penetration and accurate drug release in a focus area are realized through targeted function modification; the Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG-M / Erg-CHPG- the nerve function defect and brain tissue damage after ischemic stroke are improved, and a new technical scheme is provided for precise treatment of central nervous system diseases such as cerebral stroke.

The application relates to an IL-10 high-expression mesenchymal stem cell secretion component, a preparation method thereof and application thereof in prevention and treatment of ischemic cerebral stroke, and belongs to the technical field of cerebral stroke treatment. In order to solve the problems existing in the current stem cell clinical medication and administration method for ischemic cerebral stroke, the application provides a specially treated mesenchymal stem cell secretion component (hMSC-M), the secretion component is an IL-10 high-expression stem cell secretion component obtained by using a basic culture medium containing human IFN-gamma protein and TNF-alpha simulation peptide to induce human mesenchymal cells after expansion, and then harvesting culture and repeatedly freezing and thawing. The application finds that the hMSC-M has a significant effect on prevention and treatment of ischemic cerebral stroke through animal experiments, thereby opening up a new drug use for stem cell application, laying a foundation for developing high-efficiency related drugs for preventing and treating ischemic cerebral stroke injury, and providing a new application scheme and thought.

The invention provides a traditional Chinese medicine preparation for cerebral arterial thrombosis, and belongs to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is prepared from gentiana macrophylla, divaricate saposhnikovia root, mulberry leaf, radix scrophulariae, ruddle, bulbus fritillariae cirrhosae, bamboo juice, selfheal, poria with hostwood and szechwan chinaberry fruit, and the whole formula has the effects of calming liver and suppressing yang, calming endogenous wind and relieving convulsion, eliminating phlegm and inducing resuscitation. The traditional Chinese medicine preparation has a remarkable improvement effect on the neurological function of a cerebral ischemia reperfusion injury model rat, can effectively reduce the water content of the brain tissue of the rat and the cerebral infarction volume, remarkably improves the levels of GSH and SOD in the brain tissue of the rat, reduces the MDA level, and has the effect of improving oxidative stress induced by cerebral ischemia reperfusion. The traditional Chinese medicine preparation can effectively relieve neurological function loss of a patient suffering from cerebral arterial thrombosis, help to recover life functions of the patient and relieve clinical symptoms of the patient, is definite and remarkable in curative effect and can be used as a new medicine for treating cerebral arterial thrombosis.

The invention discloses mizoribine for treating cerebral arterial thrombosis. It is found for the first time that mizoribine can reduce the cerebral apoplexy infarction area, inhibit immune cell infiltration of the brain, relieve inflammation of the cerebral parenchyma stroke part, improve damage to the nervous system of the stroke part and promote recovery of the damaged nerve function.

Extracellular vesicles and / or exosomes (EVs) remain sparsely studied in hemorrhagic transformations, including stroke and intracranial hemorrhages and could provide key insights into stroke pathophysiology. We assessed plasma levels of neuron-derived EVs (NDEs), astrocyte-derived EVs (ADEs), and oligodendrocyte-derived EVs (ODEs) in 58 patients 5, 15, and 30 days post-ischemic stroke along with 46 matched controls using sandwich immunoassays. Hemorrhagic transformation was a better predictor of ADE levels than lesion volume in linear regression models. These findings suggest that ADE levels are preferentially increased over the first month post-stroke compared to EVs from other neural cell types. ADEs may be of additional interest as biomarkers of blood-brain barrier breakdown to predict hemorrhagic transformation at earlier time points after stroke.

The invention describes catheter systems and methods for accessing the brain during endovascular / neurointervention procedures in the treatment of ischemic stroke. More specifically, a multi-axial catheter system and kit is described that improves the process of accessing a carotid artery particularly in patients having a tortuous aortic arch and thereafter improves the process of gaining access to the brain to enable the insertion of aspiration and / or the deployment clot retrieval devices. In addition, methods of utilizing these systems are described.

The invention relates to a mesenchymal stem cell-nano knapsack system, preparation thereof and application of the mesenchymal stem cell-nano knapsack system in treatment of cerebral arterial thrombosis. The invention constructs an engineered mesenchymal stem cell-thrombin responsive nano knapsack for sequential targeted delivery of rtPA, antioxidant active molecules and MSCs for ischemic stroke treatment. In a sequential delivery mode, firstly, a thrombus site is targeted, the thrombin is responded to release rtPA for thrombolysis, brain blood supply is recovered, and the rtPA thrombolysis efficiency is improved. The antioxidant active molecules are entrapped on the erythrocyte membrane bionic nanoparticles, are loaded on the surfaces of the MSCs in a knapsack form, penetrate through BBB and tend to damage ischemic penumbra and release the antioxidant active molecules by means of central transport and inflammatory homing effects of the MSCs, on one hand, oxidative stress is inhibited, a microenvironment beneficial to activity maintenance is provided for the MSCs, and on the other hand, the antioxidant active molecules are released; and meanwhile, the medicine cooperates with MSCs to play a role in protecting injured nerve and blood vessel units, so that the treatment effect on cerebral arterial thrombosis is improved.